ATE525484T1 - Slco1b3-genotyp - Google Patents

Slco1b3-genotyp

Info

Publication number
ATE525484T1
ATE525484T1 AT08713083T AT08713083T ATE525484T1 AT E525484 T1 ATE525484 T1 AT E525484T1 AT 08713083 T AT08713083 T AT 08713083T AT 08713083 T AT08713083 T AT 08713083T AT E525484 T1 ATE525484 T1 AT E525484T1
Authority
AT
Austria
Prior art keywords
methods
determining
prostate cancer
differences
slco1b3
Prior art date
Application number
AT08713083T
Other languages
English (en)
Inventor
William Figg
Alex Sparreboom
Akinobu Hamada
Douglas Price
Tristan M Sissung
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE525484T1 publication Critical patent/ATE525484T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08713083T 2007-01-08 2008-01-08 Slco1b3-genotyp ATE525484T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87950307P 2007-01-08 2007-01-08
PCT/US2008/000310 WO2008086002A2 (en) 2007-01-08 2008-01-08 Slco1b3 genotype

Publications (1)

Publication Number Publication Date
ATE525484T1 true ATE525484T1 (de) 2011-10-15

Family

ID=39609290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08713083T ATE525484T1 (de) 2007-01-08 2008-01-08 Slco1b3-genotyp

Country Status (6)

Country Link
US (1) US10094836B2 (de)
EP (1) EP2115173B1 (de)
AT (1) ATE525484T1 (de)
AU (1) AU2008205330B2 (de)
CA (1) CA2674788A1 (de)
WO (1) WO2008086002A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572036A (en) 2008-10-15 2010-03-26 Nikola Kirilov Kasabov Data analysis and predictive systems and related methodologies
US10273544B2 (en) 2010-02-11 2019-04-30 Dana-Farber Cancer Institute, Inc. Methods for predicting likelihood of responding to treatment
EP2614158A4 (de) * 2010-09-08 2014-03-19 Mayo Foundation Vorhersage von reaktionen auf eine androgendeprivationstherapie
CN102952872B (zh) * 2011-08-29 2014-06-18 益善生物技术股份有限公司 一种slco1b3基因多态性检测特异性引物和液相芯片
EP3022562A4 (de) 2013-07-15 2017-05-17 The Cleveland Clinic Foundation 3b-hydroxysteroiddehydrogenase bei steroid-abhängiger krankheit
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
US12071669B2 (en) 2016-02-12 2024-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
US20210291189A1 (en) * 2016-08-11 2021-09-23 Siemens Healthcare Diagnostics Inc. Heating device for a filtration assembly
CN112415206B (zh) * 2020-10-23 2023-08-18 上海良润生物医药科技有限公司 外泌体中的cd171蛋白作为肿瘤转移诊断标志物的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US7258973B2 (en) * 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
US7169187B2 (en) 1999-12-22 2007-01-30 Ethicon, Inc. Biodegradable stent
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
JP2003144176A (ja) 2000-12-27 2003-05-20 Inst Of Physical & Chemical Res 遺伝子多型の検出方法
CA2437784A1 (en) * 2001-02-09 2002-08-22 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
AU784552B2 (en) 2001-03-02 2006-05-04 Cardinal Health 529, Llc Flexible stent
AU2002307466A1 (en) * 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
AUPR969201A0 (en) 2001-12-20 2002-01-24 White, Geoffrey H. A device for use in intraluminal grafting
GB0213579D0 (en) 2002-06-13 2002-07-24 Astrazeneca Ab Methods
US20050163821A1 (en) 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
EP1552001A4 (de) 2002-09-19 2006-01-04 Applera Corp Verfahren und zusammensetzungen zum nachweis von zielen
US20050149166A1 (en) 2003-11-08 2005-07-07 Schaeffer Darin G. Branch vessel prosthesis with anchoring device and method
US7468070B2 (en) 2004-01-23 2008-12-23 Boston Scientific Scimed, Inc. Stent delivery catheter
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery

Also Published As

Publication number Publication date
US10094836B2 (en) 2018-10-09
WO2008086002A2 (en) 2008-07-17
EP2115173A2 (de) 2009-11-11
WO2008086002A3 (en) 2008-10-23
AU2008205330B2 (en) 2014-07-03
US20100317726A1 (en) 2010-12-16
EP2115173B1 (de) 2011-09-21
CA2674788A1 (en) 2008-07-17
AU2008205330A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE525484T1 (de) Slco1b3-genotyp
CO7160023A2 (es) Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática
GB201021289D0 (en) Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
IL233098A (en) Methods for detecting cancer and determining prognosis and survival probabilities and ratio based biomarkers for use therein
AR066725A1 (es) Prediccion del pronostico para melanoma de cancer
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
IN2013CN01129A (de)
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
DK2208070T3 (da) Diagnostisk prædiktiv og prognostisk test for cancer
MX2013003077A (es) Diagnostico de cancer de mama.
ZA200803517B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
IL190852A0 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200804509B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2010004589A3 (en) Genetic variants predictive of cancer risk in humans
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2012166899A3 (en) Biomarkers for predicting and assessing responsiveness to lenvatinib compounds
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
BR112012026536A2 (pt) sistemas e métodos para predizer deficiência gastrointestinal
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
WO2011082198A3 (en) Cancer biomarkers to predict recurrence and metastatic potential
BRPI0716391A2 (pt) método de previsão de metástase distante de câncer de mama primário nódulo linfático-negativo usando análise de expressão gênica de via biloógica
IL205347A0 (en) Process for predicting the prognosis of squamous cell lung cancer
EP1934603A4 (de) Biomarker für prostatakrebs
WO2008061527A3 (de) Prognostische marker für die klassifizierung von kolorektalen karzinomen basierend auf expressionsprofilen von biologischen proben
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties